Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
BNTC · Why this verdict
Why Benitec Biopharma (BNTC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine classifies this as a speculative-suitability holding specifically because biotechnology is a binary industry, where clinical trial outcomes can swing the stock dramatically in either direction. Suitability rationale | The company should post at least 2 consecutive earnings beats out of the next 4 reported quarters over the next 12 months to demonstrate more predictable execution. | →Stable |
| CounterThe trailing earnings record already shows 2 beats and 2 misses over the last 4 quarters, roughly a coin flip, consistent with the binary-outcome classification rather than a deteriorating trend. | ||
Quality sits below the engine's 4.0 floor at 1.5, reflecting negative free cash flow and no competitive moat typical of a pre-revenue biotechnology company. Bear case | Free cash flow should trend toward breakeven and quality should climb above 4.0 over the next 12 months as clinical progress translates to a stronger balance sheet. | →Stable |
| CounterCash burn is expected and often not disqualifying for clinical-stage biotechs, where value is driven by pipeline progress rather than current profitability. | ||
The stock is in a momentum-continuation setup with RSI at 67 and bullish MACD, producing an asymmetry ratio of 4.65 with 69.8% modeled upside against a 15% downside. Chart pattern detection | Price should continue trending higher with momentum staying above the engine's 5.5 threshold over the next 12 months for the continuation thesis to hold. | →Stable |
| CounterA death-cross warning under recovery status shows the technical picture is not unambiguously bullish, and momentum could reverse before the asymmetric upside is realized. | ||
Analysts model 95% upside for the stock, one of the largest modeled gains in the dataset, reflecting high expectations for clinical or commercial catalysts. Sentiment breakdown | The stock should track toward the analyst target with upside narrowing from 95% toward single digits over the next 12 months as the thesis plays out. | →Stable |
| CounterA 95% upside target on a speculative biotech can reflect binary clinical-trial outcomes that either fully validate or fully invalidate the price target, with limited middle ground. | ||
Short interest sits at 12%, an elevated level that signals a meaningful contingent of investors positioned against the stock. Key risks | Short interest should decline toward single digits below 8% over the next 12 months if bearish positioning is unwinding. | →Stable |
| CounterElevated short interest combined with high implied volatility of 137% raises the possibility of a short squeeze if a positive clinical catalyst emerges. | ||
The engine classifies this as a speculative-suitability holding specifically because biotechnology is a binary industry, where clinical trial outcomes can swing the stock dramatically in either direction.
→StableSuitability rationale
- Expectation
- The company should post at least 2 consecutive earnings beats out of the next 4 reported quarters over the next 12 months to demonstrate more predictable execution.
CounterThe trailing earnings record already shows 2 beats and 2 misses over the last 4 quarters, roughly a coin flip, consistent with the binary-outcome classification rather than a deteriorating trend.
Quality sits below the engine's 4.0 floor at 1.5, reflecting negative free cash flow and no competitive moat typical of a pre-revenue biotechnology company.
→StableBear case
- Expectation
- Free cash flow should trend toward breakeven and quality should climb above 4.0 over the next 12 months as clinical progress translates to a stronger balance sheet.
CounterCash burn is expected and often not disqualifying for clinical-stage biotechs, where value is driven by pipeline progress rather than current profitability.
The stock is in a momentum-continuation setup with RSI at 67 and bullish MACD, producing an asymmetry ratio of 4.65 with 69.8% modeled upside against a 15% downside.
→StableChart pattern detection
- Expectation
- Price should continue trending higher with momentum staying above the engine's 5.5 threshold over the next 12 months for the continuation thesis to hold.
CounterA death-cross warning under recovery status shows the technical picture is not unambiguously bullish, and momentum could reverse before the asymmetric upside is realized.
Analysts model 95% upside for the stock, one of the largest modeled gains in the dataset, reflecting high expectations for clinical or commercial catalysts.
→StableSentiment breakdown
- Expectation
- The stock should track toward the analyst target with upside narrowing from 95% toward single digits over the next 12 months as the thesis plays out.
CounterA 95% upside target on a speculative biotech can reflect binary clinical-trial outcomes that either fully validate or fully invalidate the price target, with limited middle ground.
Short interest sits at 12%, an elevated level that signals a meaningful contingent of investors positioned against the stock.
→StableKey risks
- Expectation
- Short interest should decline toward single digits below 8% over the next 12 months if bearish positioning is unwinding.
CounterElevated short interest combined with high implied volatility of 137% raises the possibility of a short squeeze if a positive clinical catalyst emerges.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Benitec Biopharma is a speculative, cash-burning biotech with sub-floor quality, but a momentum-continuation setup and 95% analyst upside give it an asymmetric risk/reward typical of a binary clinical-stage name.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 8.8 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 4.5 |
- ▸Analyst upside: 91%
Insider
5.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 6.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 2.0 |
| 52w position | 5.7 |
Risk (lower is worse)
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.8 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 10.0 |
- ▸High IV: 184%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.7 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.4>=5.5
- ASYMMETRY:4.4>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:76d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=6.4>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
4.43
Upside
+66.5%
Downside
15.0%
Sizing output
AVOID
SetupMomentum Cont — Trend continuation, RSI 69, MACD bullish
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 6.5, and Momentum at 6.4; the weakest are Quality at 1.6, Technical at 3.3, and Catalyst at 4.0. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 4.43 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Floor Cash Burning Biotech
Trip ifFree cash flow margin rises above -20% of revenue from the current cash-burning level.
- P2Momentum Continuation With High Asymmetry
Trip ifMomentum score falls below 5.5, breaking the current continuation setup at 7.3.
- P3Analyst Upside 95 Percent
Trip ifUpside to the analyst target narrows below 20% from the current 95% as price appreciates.
- P4Elevated Short Interest
Trip ifShort interest falls below 8% of float from the current 12%.
- P5Binary Biotech Speculative Suitability
Trip ifThe company posts fewer than 2 earnings beats over the next 4 reported quarters.